Drugs / GC511B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07249879 | Mar → Nov 2026 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC511B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07249879 ↗ |
| Modality | Cell therapy | “lentiviral gene-modified autologous chimeric antigen receptor T-cell product” NCT07249879 ↗ |
| Route | Intravenous | “Single IV infusion.” NCT07249879 ↗ |